Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, Vesalius Biocapital Partners appears to focus on early to growth-stage biotech investments, particularly in therapeutic areas including autoimmune disease, neurodegenerative conditions, and women's health, despite fintech being listed as a sector. Recent portfolio suggests a concentration in life sciences rather than financial technology, with check sizes ranging from €0.2M to €10.0M across multiple funding stages.
Generated 7 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Vesalius Biocapital Partners's website.
Seasoned life science professional with deep expertise in start-up maturation.
PhD with extensive experience in maturing start-up companies through technical and business insights.
PhD with extensive experience in maturing start-up companies through technical and business insights.
Seasoned life science professional with deep expertise in start-up maturation.
Seasoned life science professional with deep expertise in start-up maturation.
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.